Michael has represented a variety of major life sciences companies in litigation matters. In the pharmaceutical field, he has played a significant role in litigations involving drug products including: ertapenem (Invanz, cabazitaxel (Jevtana), naltrexone/bupropion (Contrave), paricalcitol (Zemplar), diclofenac (Cambia), lansoprazole (Prevacid Solutabs), valganciclovir (Valcyte), cefdinir (Omnicef), minocycline (Solodyn), amlodipine besylate (Norvasc), and alendronate (Fosamax). In addition to his district court experience, Michael has prevailed in several appeals following trials and preliminary injunction decisions.

Michael’s practice also includes client counseling on patent infringement, validity, and enforceability, as well as intellectual property issues associated with transactional work including licensing and mergers.

Nautilus v. Wockhardt & Edict (diclofenac) – Represented a branded pharmaceutical company against two generic challengers on four patents related to novel formulations and methods of treatment for diclofenac.

Arkema v. Honeywell – Currently representing a chemical company in a declaratory judgment action seeking to invalidate patents directed to 1234yf, a hydrofluorocarbon used in automobile refrigeration.

Takeda v. Teva (lansoprazole) – Successfully represented Teva in the Federal Circuit on an appeal from a district court decision of non-infringement. The Federal Circuit affirmed the district court’s decision one day after oral argument.

Selected Professional and Business Activities

Michael is a member of the New York Intellectual Property Law Association where he currently serves as Co-Chairperson of the Programs Committee. Michael is also a member of the American Intellectual Property Association.